Antares Vision Group has launched DIAMIND Sentry, a solution designed to allow pharma companies to efficiently manage the substantial uptick in exceptions stemming from traceability mandates. The system was developed by rfxcel, a business unit of Antares providing supply chain visibility solutions.

The implementation of widespread traceability regulations, notably the FDA’s Drug Supply Chain Security Act (DSCSA), requires the electronic exchange of unit-level product data, amplifying the volume of information shared among manufacturers, wholesalers, and dispensers. However, any errors during these exchanges result in compliance exceptions, and a significant increase in these exceptions has created industry-wide challenges. 

DIAMIND Sentry was developed to help address these exception-centric obstacles by streamlining collaboration and ensuring seamless regulatory compliance. The cloud-based platform allows manufacturers, wholesalers, and dispensers to identify and resolve product data exchange errors. Importantly, the system’s exception management capabilities do not require platform upgrades, helping to clear the way for rapid deployment.

DIAMIND Sentry automatically evaluates inbound and outbound Electronic Product Code Information Services (EPCIS) files through multiple prechecks, including format and master data validation, ensuring they meet DSCSA standards. Files that fail any checks generate detailed validation reports. Depending on the error’s criticality, files are either blocked, flagged for review, or sent back to partners for correction. Here, automated notifications and ticketing systems help to facilitate quick resolution of issues, allowing partners to respond directly via email to trigger automated responses and reprocessing.